AI Earnings Predictions for Paysign Inc. (PAYS)

EX-99.1

2 paysign_ex9901.htm

EARNINGS RELEASE

Exhibit 99.1

Earnings Release

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses

Mix Shift and Expense Discipline Continue to Drive Gross and Operating Margin Expansion

Balance Sheet Supports Continued Investment and Growth Initiatives

HENDERSON, Nev. – August 5, 2026 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the second quarter 2026.

Second Quarter 2026 Financial Highlights

· Revenues of $28.25 million in Q2’26, up 48.1% from Q2’25

· Pharma revenue increased to $14.65 million in Q2’26, an increase of 88.9% versus Q2’25; added 51 net patient affordability programs during the past 12 months, exiting the quarter with 148 active programs

· Plasma revenue increased to $13.04 million in Q2’26, an increase of 21.4% versus Q2’25; total net plasma center count decreased by 46 during the past 12 months, exiting the quarter with 561 centers.

· Gross profit margin was 63.3% in Q2’26 compared to 61.6% in Q2’25

· Operating margin increased to 24.8% in Q2’26, up from 7.5% from Q2’25; excluding the fair value adjustment on contingent consideration, operating margin increased to 21.3%1

· GAAP net income of $6.76 million, or $0.11 per fully diluted share, in Q2’26 versus GAAP net income of $1.39 million, or $0.02 per fully diluted share in Q2’25

· Adjusted EBITDA of $9.61 million in Q2’26, up 113.0% from $4.51 million for Q2’25; diluted Adjusted EBITDA per share of $0.16 versus $0.08 for Q2’251

· Exited the quarter with $27.37 million of unrestricted cash and zero bank debt

· Second quarter 2026 gross dollar load volume was up 24.3% versus second quarter 2025

· Second quarter 2026 gross spend volume was up 24.2% versus second quarter 2025

· Raising full-year 2026 outlook – revenue $114.0 million to $117.0 million; Adjusted EBITDA $35.0 million to $38.0 million

1Adjusted EBITDA, Adjusted EBITDA per share, and Adjusted operating margin are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted EBITDA and operating income margin to Adjusted operating margin at the end of the press release.

“Paysign delivered a strong second quarter, achieving record revenue, net income, and adjusted EBITDA while continuing to expand margins,” said Mark Newcomer, President and CEO of Paysign. “Strong growth in our patient affordability business, steady performance in plasma donor compensation, and disciplined execution across the company drove meaningful operating leverage and profitability, reinforcing the multiyear strategy we have been building. With momentum across the business and a robust pipeline of opportunities, we intend to remain focused on sustainable growth, continued margin expansion, and creating long-term value for shareholders.”

1

2026 Second Quarter Results

Total revenues increased 48.1%, or $9.17 million, to $28.25 million, up from $19.08 million in the second quarter of 2025. Pharma industry revenue increased 88.9% to $14.65 million from $7.75 million due to the financial benefit of 51 net pharma patient affordability programs launched during the past 12 months, and a corresponding increase in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and customer service contact center support. Processed claims increased by approximately 54% compared to the second quarter of 2025. Plasma revenue increased 21.4% to $13.04 million, up from $10.74 million, primarily due to an increase in plasma donations and dollars loaded to cards, offset by the reduction of 46 net plasma centers during the past 12 months. The decline in net plasma centers reflected customer center closures and the sale of certain customer centers to a company that uses another provider. The average monthly revenue per center increased to $7,699 versus $7,098 and the average number of loads per center increased, representing stronger utilization at existing centers. We exited the quarter with 561 centers versus 607 centers in the second quarter of 2025.

Cost of revenues increased 41.4% to $10.36 million due to related costs associated with the growth in our businesses including network and related costs, call center support costs, a new customer service contact center that went live in November 2025 and higher employee costs. Gross profit margin improved to 63.3% compared to 61.6% in the second quarter of 2025 as we experienced a greater mix of pharma revenue.

Total operating expenses were $10.89 million compared to $10.32 million in the second quarter of 2025, an increase of 5.5%. During the

EX-99.1

2 paysign_ex9901.htm

EARNINGS RELEASE

Exhibit 99.1

Earnings Release

Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

Mix Shift Continues to Deliver Expansion in Gross and Operating Margin

Strong Balance Sheet Enables Continued Investment for Profitable Growth

HENDERSON, Nev. – May 12, 2026 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the first quarter 2026.

First Quarter 2026 Financial Highlights

· First quarter 2026 revenues of $28.04 million, up 50.8% from first quarter 2025

· First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus first quarter 2025; added 45 net patient affordability programs during the past twelve months, exiting the quarter with 135 active programs

· First quarter 2026 plasma revenue increased to $11.75 million, an increase of 24.9% versus first quarter 2025; total net plasma center count increased by 89 during the past 12 months, exiting the quarter with 573 centers

· First quarter 2026 operating margin was 23.8% compared to 13.4% in the first quarter 2025

· First quarter 2026 net income of $5.44 million, or $0.09 per diluted share, versus net income of $2.59 million, or $0.05 per diluted share in the first quarter 2025

· First quarter 2026 adjusted EBITDA of $10.59 million, up 113.4% from $4.96 million for first quarter 2025; diluted Adjusted EBITDA per share of $0.17 versus $0.09 for first quarter 20251

· Exited the quarter with $20.55 million of unrestricted cash and zero bank debt

· First quarter 2026 restricted cash balances increased 10.4% to $158.95 million from first quarter 2025

· First quarter 2026 gross dollar load volume was up 26.4% versus first quarter 2025

· First quarter 2026 gross spend volume was up 26.7% versus first quarter 2025

1Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted EBITDA at the end of the press release.

“Paysign delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction and the scalability of the platform we’ve built,” said Mark Newcomer, President and CEO of Paysign. “Our plasma donor compensation business continues to perform exceptionally well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe and Asia reinforces our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive advantage. Patient affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong pipeline that reflects the trust pharmaceutical manufacturers place in Paysign to help patients access and afford the therapies they need. As this business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we serve.”

1

2026 First Quarter Results

Total revenues increased 50.8%, or $9.44 million, to $28.04 million, up from $18.6 million in the first quarter of 2025. Pharma industry revenue increased 81.9% to $15.68 million from $8.62 million due to the financial benefit of 45 net pharma patient affordability programs launched during the past 12 months, and a corresponding increase in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and customer service contact center support. Processed claims increased by approximately 49% compared to the first quarter of 2025. Plasma revenue increased 24.9% to $11.75 million, up from $9.41 million, primarily due to the addition of 89 net plasma centers added during the past 12 months. The average monthly revenue per center increased to $6,671 versus $6,517 and the average number of loads per center increased for the first time since the industry experienced an inventory correction that began in 2024. We exited the quarter with 573 centers versus 595 centers at the end of 2025 as 20 centers were sold to companies who use a competing provider and two underperforming centers were closed. Combined, these centers averaged less than $3,500 per month in revenue, performing below the corporate average.

Cost of revenues increased 42.2% due to increased call center support expense associated with the revenue growth, a new customer service contact center that went live in November 2025 and higher employee costs. Gross profit improved to 65.0% compared to 62.9% in the first quarter of 2025 as we experienced a greater mix of pharma revenue.

Total operating expenses were $11.55 million compared to $9.20 million in the first quarter of 2025, an increa

EX-99.1

2 paysign_ex9901.htm

EARNINGS RELEASE

Exhibit 99.1

Earnings Release

Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion

Mix Shift Drives Gross and Operating Margin Expansion

Strong Balance Sheet Enables Continued Investment for Profitable Growth

HENDERSON, Nev. – March 24, 2026 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the fourth quarter and full-year 2025.

Full-Year Financial Highlights

· Full-year 2025 total revenues of $82.0 million, up 40.5% from 2024

· Total net plasma center count increased by 115 during 2025, exiting the year with 595 centers, contributing to a 4.0% increase in plasma revenue versus the same period last year

· Added 55 net patient affordability programs during 2025, exiting the year with 131 active programs, leading to a 167.8% increase in pharma revenue over the same period last year

· Patient affordability claim volume increased over 79% during 2025 versus the same period last year

· Full-year 2025 net income of $7.55 million, or $0.13 per diluted share, versus net income of $3.82 million, or $0.07 per diluted share for full-year 2024

· Full-year 2025 Adjusted EBITDA of $19.94 million, up 107.3% from $9.62 million a year ago, while diluted Adjusted EBITDA per share was $0.33 versus $0.17 for full-year 20241

· Exited the year with $21.07 million of unrestricted cash and zero debt while repurchasing 100,000 shares of common stock for $376 thousand

· Restricted cash balances increased 29.0% to $143.92 million

· Gamma Innovation LLC (“Gamma”) acquisition closed on March 19, 2025 with Blood Establishment Computer System (BECS) currently under U.S. Food and Drug Administration review

· Full-year 2025 gross dollar load volume was up 8.5% over 2024

·

Full-year 2025 gross spend volume was up 6.2% over 2024

· Full-year 2025 effective tax rate of 24.7% versus 7.8% for the same period last year

1

Fourth Quarter Financial Highlights

· Fourth quarter 2025 total revenues of $22.76 million, up 45.8% from fourth quarter 2024 (“Q4 2024”)

· Fourth quarter 2025 net income of $1.36 million, or $0.02 per diluted share, versus net income of $1.37 million, or $0.02 per diluted share for Q4 2024

· Fourth quarter 2025 Adjusted EBITDA of $5.43 million, up 89.6% from $2.86 million for Q4 2024, while diluted Adjusted EBITDA per share was $0.09 versus $0.05 for Q4 20241

· Plasma revenue of $12.60 million was up 16.7% versus the same period last year

· Fourth quarter 2025 average revenue per plasma center per month of $7,067, down from $7,510 for Q4 2024

· Pharma revenue of $9.60 million was up 122.4% versus the same period last year

· Fourth quarter 2025 patient affordability claim volume increased over 49% versus Q4 2024

· Fourth quarter 2025 gross dollar load volume was up 20.7% compared to Q4 2024

· Fourth quarter 2025 gross spend volume was up 20.4% compared to Q4 2024

· Fourth quarter 2025 effective tax rate of 45.4% versus (11.1%) for the same period last year

1Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted EBITDA at the end of the press release.

“2025 was a standout year for Paysign, delivering record top- and bottom-line results,” commented Mark Newcomer, President and CEO of Paysign. “We delivered continued, steady growth in our plasma compensation business and our differentiated solution for patient affordability enabled growth of more than 167%. We continued to scale our patient affordability platform, adding 55 net patient affordability programs during 2025, validating our focus on this business line and demonstrating our ability to generate a positive return on investment for pharmaceutical customers while improving patient access to copay funds. Patient affordability has become a primary driver of both growth and profitability. Demand for our differentiated solutions is strong and growing, reflecting the value of our technology, service model and real-time claims capabilities.”

“As patient affordability continues to represent a larger portion of our business, the benefits of a more favorable revenue mix, with higher margins and increased operating leverage, are translating to the bottom line,” Newcomer added. “We believe we remain in the early stages of this opportunity and are well positioned to continue expanding our presence in the life sciences ecosystem.”

2025 Full-Year Results

Total revenues increased 40.5%, or $23.64 million to $82.02 million from $58.38 million in 2024. Pharma industry revenue increased 167.8% to $33.89 million from $12.65 million due to the financial benefit of